PulseAugur
EN
LIVE 22:03:35
中文(ZH) 欧科亿：股东询价转让定价为96.45元/股，较今日收盘价折价31.1%

Fosun Pharma invests 414M yuan in liver disease drug developer Starry Kunze

By PulseAugur Editorial · [1 sources] ·

Fosun Pharma's subsidiary, Fosun Pharma Industry, is investing 414 million yuan in Starry Kunze's Series B funding round. This investment includes subscribing to new capital and acquiring existing shares, which will result in Fosun Pharma Industry holding a 20.87% stake in Starry Kunze. The target company focuses on the research and development of innovative drugs for liver diseases, aiming to expand Fosun Pharma's pipeline in this therapeutic area. AI

IMPACT Minimal direct impact on AI operators; this is a pharmaceutical industry funding event.

RANK_REASON Significant investment round in a biotech company by a major pharmaceutical player. [lever_c_demoted from significant: ic=1 ai=0.1]

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Fosun Pharma invests 414M yuan in liver disease drug developer Starry Kunze

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Research
Significant investment round in a biotech company by a major pharmaceutical player. [lever_c_demoted from significant: ic=1 ai=0.1]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
funding, product
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
105 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    OKAY: Shareholders' inquiry transfer priced at 96.45 yuan/share, a 31.1% discount to today's closing price

    36氪获悉，欧科亿公告，根据2026年5月26日询价申购情况，初步确定的本次询价转让价格为96.45元/股。参与报价的机构投资者共65家，有效认购倍数为2.36倍，拟受让股份总数为8732993股。

RELATED TOPICS